Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Between Novo and Lilly, the GLP-1 industry has become an oligopoly with even less threat from compounders like Hims & Hers Health Inc. HIMS after being taken off the drug shortage list.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

An ad for compounded versions of weight-loss drug semaglutide by telehealth company Hims & Hers has attracted ... of a prescription medicine. GLP-1 agonist semaglutide is the active ingredient ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Hims & Hers Health ( HIMS 3.08%) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach ...

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company ...

I’ve got my eye on four trends – the maturation of AI-powered drug development, fierce competition in the GLP-1 space ... She began her career as a clinical research coordinator at the ...

The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies ...